A Dose of Hope: Cognition's CT1812 Proves Its Mettle in Alzheimer's Aβ Oligomer Displacement
Portfolio Pulse from Vandana Singh
Cognition Therapeutics announces data publication from a Phase 1b SNAP trial of CT1812, showing its effectiveness in displacing Aβ oligomers in Alzheimer's patients. The study demonstrated that a single oral dose of CT1812 rapidly displaces Aβ oligomers from synapses, with no serious adverse events related to the medication.
May 18, 2023 | 5:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cognition Therapeutics' CT1812 shows positive results in Phase 1b SNAP trial for Alzheimer's treatment, leading to a 14.70% increase in stock price.
The positive results from the Phase 1b SNAP trial of CT1812 demonstrate its effectiveness in displacing Aβ oligomers in Alzheimer's patients. This is a significant development in Alzheimer's treatment, which has led to a 14.70% increase in Cognition Therapeutics' stock price. As the company continues to develop and test CT1812, further positive results could lead to additional stock price increases.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100